The new patent is the 13th issued in the ophthalmic family, with 20 others pending. It continues and expands US Patent No. 7,665,467, with broad claims covering the use of laser technology for treating various conditions of the eye, including presbyopia — the inability to focus sharply for near vision — and it opens up opportunities in oculoplastics as well as the treatment of cataracts and glaucoma.

In other news, the company has formed a Oculase Inc., a wholly owned subsidiary based in Delaware. The new entity will own and develop the company’s ophthalmic assets and technologies. Biolase said it plans to develop an operating unit at the new venture to focus specifically on diseases and conditions of the eye.